Skip to content

Clinical trials

Heart Failure trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Heart Failure Country / region: China Clear all

284 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20051
20063
20072
20083
20094
20102
20112
20128
201312
201413
201510
201614
201715
20187
20196
202016
202121
202220
202333
202433
202530
202627

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status85
Completed73
Recruiting71
Not yet recruiting19
Terminated13
Active, not recruiting12
Enrolling by invitation7
Suspended3
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
China National Center for Cardiovascular Diseases9
Hebei Medical University8
Medtronic Cardiac Rhythm and Heart Failure8
Ruijin Hospital8
Shanghai Zhongshan Hospital8
Second Affiliated Hospital, Zhejiang University, School of Medicine7
AstraZeneca6
Chinese Academy of Medical Sciences, Fuwai Hospital6
HELP Therapeutics Co., Ltd.6
Novartis Pharmaceuticals6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Heart Failure284
Atrial Fibrillation20
Cardiovascular Diseases17
Hypertension, Pulmonary9
Coronary Artery Disease8
Arrhythmias, Cardiac7
Cardiomyopathy, Dilated6
Hypertension6
Stroke6
Bradycardia5

Trials

Showing 76 to 100 of 284. Each trial links to its page on Pharma Observatory.

184 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.